Market Overview

UPDATE: Canaccord Genuity Decreases PT on Delcath Systems to $5

Share:
Related DCTH
12 Biggest Mid-Day Losers For Thursday
15 Biggest Mid-Day Losers For Wednesday
Retrospective study shows treatment benefit of PHP in metastatic ocular melanoma patients; Delcath up 46% (Seeking Alpha)

According to a research report this morning, Canaccord Genuity decreases its PT on Delcath Systems (NASDAQ: DCTH) from $8 to $5.

Canaccord Genuity explained, ‘These physicians provided an interesting perspective about how CHEMOSAT fits in the oncology armamentarium. We reduce our forward estimates and price target – to $5.00 from $8.00 – to reflect dilution related to the recent equity offering and previously announced delay of the NDA filing (mid-August-E).”

Delcath Systems closed Friday at $1.44 as Canaccord Genuity maintains its Buy rating.

Latest Ratings for DCTH

DateFirmActionFromTo
Mar 2016WallachbethInitiates Coverage onBuy
May 2013WedbushDowngradesOutperformNeutral
May 2013JMP SecuritiesDowngradesMarket OutperformMarket Perform

View More Analyst Ratings for DCTH
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Reiteration Analyst Ratings

 

Related Articles (DCTH)

View Comments and Join the Discussion!